NCT00253578已完成2 期
A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients With Relapsing or Resistant Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Overall response rate (confirmed CR, R and PR)
研究概览
简要总结
This phase II trial is studying how well sorafenib works in treating patients with relapsed or refractory multiple myeloma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer
详细描述
PRIMARY OBJECTIVES:
I. To assess the overall response rate (confirmed CR, R and PR) in patients with relapsed/refractory multiple myeloma treated with BAY 43-9006.
II. To evaluate qualitative and quantitative toxicities associated with this regimen.
III. To assess overall and progression-free survival in this group of patients treated with this regimen.
IV. To explore, in a preliminary manner, associations between gene expression signatures and response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a confirmed diagnosis of previously treated, active multiple myeloma, with measurable disease present to evaluate response; all tests for establishing baseline disease status (serum protein electrophoresis, urine protein electrophoresis and bone marrow biopsy) must be performed within 28 days prior to registration and MUST be documented on the Baseline and Follow-up Tumor Assessment Form for Multiple Myeloma
- •Patients must have relapsed or resistant disease, defined as relapsing after autologous stem cell transplantation or is either relapsing or is resistant after >= 1 line of prior therapy for myeloma; a minimum of 42 days must have elapsed since prior transplant
- •Relapse: is defined as the occurrence of any of the following during or after previous treatment:
- •A myeloma protein increase by more than 100% from the lowest previously recorded level
- •A myeloma protein increase above the response criteria for PR
- •Reappearance of any myeloma peak that had disappeared during the previous treatment
- •Increase in the size and number of lytic bone lesions and/or focal lesions recognized in radiographic studies (x-ray, MRI, PET and/or CT scans)
- •Resistant disease: is defined as disease not responding (i.e. not achieving CR, R, PR) to previous therapy
- •Patients must be off myelosuppressive chemotherapy for >= 21 days (>= 6 weeks for nitrosoureas) and non-myelosuppressive chemotherapy and XRT for >= 14 days and recovered from all treatment associated toxicities prior to registration
- •Patients must have a Zubrod Performance Status (PS) of 0-2
- •Patients must have received no prior treatment with BAY 43-9006
- •Patients must have currently have no significant neurotoxicity, defined as Grade >= 2 neurotoxicity per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
- •Patients must have no evidence of POEMS (polyneuropathy, organomegaly, endocrinopathy, presence of M-protein, and skin changes) Syndrome
- •There must be no active infection requiring antibiotics
- •Bilirubin =< 1.5 times the institutional upper limit of normal (IULN)
- •AST (SGOT or SGPT) =< 5 times the institutional upper limit of normal (IULN)
- •Serum creatinine =< the institutional upper limit of normal (IULN)
- •ANC > 750/ul
- •Platelet count > 75,000/ul
- •Patients must be able to take oral medication without crushing, dissolving or chewing tablets
- •Patients must not be taking the cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, and phenobarbital), rifampin, or St. John's Wort
- •Patients must not have a significant history of cardiac disease, e.g., uncontrolled hypertension, unstable angina, congestive-heart failure, and myocardial infarction within the last six months, or cardiac ventricular arrhythmias requiring medication
- •Patients must not have any evidence of bleeding diathesis, uncontrolled diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
- •Patients must not be on therapeutic anticoagulation
- •No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years
- •Pregnant or nursing women may not participate in this trial because of increased risk of fetal harm including fetal death from the chemotherapeutic agents; women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- •Institutions must have IRB approval of S0309 ("Myeloma Specimen Repository Protocol, Ancillary"); patients must be offered participation in S0309; with the patient's consent, bone marrow aspirates and serum specimens will be submitted for testing via S0309; patients must be registered separately to S0309 in order for institutions to receive credit for specimen submission to S0309; NOTE: immediately following S0434 registration, the CRA will need to have completed the S0309 Registration Form and eligibility worksheet in hand for use
- •All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- •At the time of patient registration, the treating institution's name and ID number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base
排除标准
- 未提供
研究组 & 干预措施
Treatment (sorafenib tosylate)
Experimental
Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: sorafenib tosylate (Drug)
Treatment (sorafenib tosylate)
Experimental
Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Overall response rate (confirmed CR, R and PR)
时间窗: Up to 3 years
Incidence of qualitative and quantitative toxicities associated with this regimen
时间窗: Up to 3 years
Overall survival
时间窗: Up to 3 years
Progression-free survival
时间窗: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaAdenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderAdenocarcinoma With Squamous Metaplasia of the GallbladderCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerSquamous Cell Carcinoma of the GallbladderUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00238212National Cancer Institute (NCI)50
已完成
2 期
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung CancerRecurrent Small Cell Lung CancerNCT00182689National Cancer Institute (NCI)89
已完成
2 期
Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase InhibitorNon-Small Cell Lung CancerNCT00922584Chinese Society of Lung Cancer65
已完成
2 期
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderNCT00112671National Cancer Institute (NCI)17
已完成
2 期
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsGastrinomaMetastatic Gastrointestinal Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaSomatostatinomaWDHA SyndromePancreatic Polypeptide TumorNeuroendocrine TumorGlucagonomaInsulinomaNCT00131911National Cancer Institute (NCI)93